NCT02648997
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 19 versions: 18 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 92 words
- Study completion pushed from Oct 1, 2026 to Apr 1, 2027
- Interventions: External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg… to External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg…
- Secondary endpoints: details revised at 4 of 4 entries
- Minor Study completion pushed from Jun 1, 2026 to Oct 1, 2026v18
Notable Results first posted: Jan 26, 2026v17 Show 5 more changesShow less
- Primary endpoint revised
- Study completion date: Dec 1, 2025 to Jun 1, 2026
- Interventions: External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 3 mg/kg (Drug), Nivolumab - 480 mg (Drug) to External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg…
- Secondary endpoints revised (4)
- Study arms: 2 to 3
Minor Trial status: Recruiting to Active, Not Recruitingv15 Show 5 more changesShow less
- Enrollment target: estimated 50 to confirmed 40
- Primary completion date: Mar 2025 to Dec 1, 2024
- Study completion date: Sep 2025 to Dec 1, 2025
- Site details revised
- Study title expanded, about 2 words
- Notable Primary completion date: Dec 2023 to Mar 2025
- Study completion date: Jun 2024 to Sep 2025
Show 12 earlier versionsHide 12 earlier versions
Notable Eligibility criteria expanded, about 5 wordsv13 Show 4 more changesShow less
- Primary completion date: Jun 2023 to Dec 2023
- Study completion date: Dec 2023 to Jun 2024
- Secondary endpoints: details revised at 4 of 4 entries
- Study title revised
- Notable Primary completion date: Oct 2021 to Jun 2023
- Study completion date: Dec 2022 to Dec 2023
- Notable Primary completion date: Feb 2021 to Oct 2021
- Study completion date: Apr 2022 to Dec 2022
- Notable Trial status: Active, Not Recruiting to Recruiting
- Interventions: External Beam RT (Radiation), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 480 mg (Drug) to External Beam RT (Radiation), Ipilimumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 3 mg/kg (Drug), Nivolumab - 480 mg (Drug)
- Site details revised
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Notable Primary completion date: Feb 2020 to Feb 2021
- Study completion date: Apr 2021 to Apr 2022
Notable Enrollment target: 25 to 50v7 Show 10 more changesShow less
- Primary completion date: Apr 2019 to Feb 2020
- Eligibility criteria expanded, about 120 words
- Primary endpoint revised
- Study completion date: Apr 2020 to Apr 2021
- Interventions: Nivolumab (Drug) to External Beam RT (Radiation), Ipilimumab - 3 mg/kg (Drug), Nivolumab - 1 mg/kg (Drug), Nivolumab - 240 mg (Drug), Nivolumab - 480 mg (Drug)
- Secondary endpoints revised (4)
- Study description expanded, about 38 words
- Study arms: 1 to 2
- Collaborators expanded, about 2 words
- Study title expanded, about 3 words
- Notable Primary completion date: Aug 2018 to Apr 2019
- Study completion date: Dec 2019 to Apr 2020
- Minor Primary completion date: Jul 2019 to Aug 2018
- Study completion date: Jul 2023 to Dec 2019
- Notable Eligibility criteria expanded, about 9 words
- Secondary endpoints: 3 to 4
- Study description revised
- Notable Eligibility criteria revisedv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 2 to 1
- Start date: Feb 2016 to Mar 2016
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (4)
Arms and interventions
Nivolumab monotherapy (240 mg every 2 weeks)
* External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy) * Followed by 4 cycles of Nivolumab (1 mg/kg every 3 weeks) + Ipilimumab (3 mg/kg every 3 weeks) * Followed by Nivolumab monotherapy (480 mg every 4 weeks).
* External Beam RT (IMRT, 3D-CRT, or proton-beam radiation therapy) * Followed by 4 cycles of Nivolumab (3 mg/kg every 3 weeks) + Ipilimumab (1 mg/kg every 3 weeks) * Followed by Nivolumab monotherapy (480 mg every 4 weeks).
Drugs: Nivolumab - 240 mg, Ipilimumab - 1 mg/kg, Nivolumab - 480 mg, Nivolumab - 3 mg/kg, Nivolumab - 1 mg/kg, Ipilimumab - 3 mg/kg
Radiation: External Beam RT
Sites
1 site in 1 country
- Dana-Farber Cancer InstituteBoston, Massachusetts, United States